Because insulin has been shown to stimulate long-chain fatty acid (LCFA) esterification in skeletal muscle and cardiac myocytes, we investigated whether insulin increased the rate of LCFA transport by altering the expression and the subcellular distribution of the fatty acid transporters FAT/CD36 and FABPpm. In cardiac myocytes, insulin very rapidly increased the expression of FAT/CD36 protein in a time-and dose-dependent manner. During a 2-h period, insulin (10 nM) increased cardiac myocyte FAT/CD36 protein by 25% after 60 min and attained a maximum after 90 -120 min (ϩ40 -50%). There was a dose-dependent relationship between insulin (10 Ϫ12 to 10 Ϫ7 M) and FAT/CD36 expression. The half-maximal increase in FAT/CD36 protein occurred at 0.5 ϫ 10 Ϫ9 M insulin, and the maximal increase occurred at 10
. In recent years, it has been shown that rates of LCFA transport can be regulated acutely and chronically. In heart and skeletal muscle exposed briefly to insulin (15 min) and in contracting muscle (Ͻ30 min), rates of LCFA transport are increased due to the translocation of FAT/CD36 from an intracellular depot to the plasma membrane (4, 18, 19) . Expression of FAT/CD36 mRNA is upregulated by LCFAs in neonatal cardiac myocytes (30) , although the functional metabolic consequences of these changes on LCFA transport and metabolism have not been determined. In more detailed studies, FAT/CD36 mRNA and protein expression and plasmalemmal FAT/CD36 were increased in 7-day chronically stimulated muscle (3) . Conversely, FAT/CD36 mRNA and protein expression and plasmalemmal FAT/CD36 were reduced by chronic leptin administration. In both of these studies, the rates of LCFA transport into muscle were altered in direct relation to the content of plasmalemmal FAT/CD36 (3, 27) .
LCFA transporters and rates of LCFA transport are also altered in obesity and diabetes. In obese Zucker rats (17) and streptozotocin (STZ)-induced diabetes (16) , LCFA transport into heart and muscle is increased through the subcellular redistribution of FAT/CD36 to the plasma membrane [obesity (17) ] and through the increased expression of FAT/CD36 and FABPpm, resulting in their increased sarcolemmal content [type 1 diabetes (16) ]. Because of the many alterations in circulating substrates and hormones in these animal models, it was not possible to determine which factor(s) accounted for the changes in LCFA transporters. But, given that LCFA transporter expression is increased in STZ-induced diabetes (16) , it is tempting to suggest that the hypoinsulinemia in this model may have contributed to the upregulation of the FAT/CD36 and FABPpm mRNAs and proteins in the heart (16) . Indeed, this is suggested by studies in 3T3-L1 adipocytes, in which insulin rapidly reduced the expression of fatty acid transport protein (FATP)-1 mRNA (21), another LCFA transporter. Whether insulin also regulates the expression of FAT/CD36 and FABPpm is not known. Therefore, in the present studies, we have examined the effects of insulin on regulating the expression of the LCFA transporters FAT/CD36 and FABPpm 1) in cardiac myocytes and 2) in perfused hearts. In addition, we determined 3) the effects of insulin on the subcellular distribution of LCFA transporters, 4) the effects of insulin on the rates of LCFA transport, and 5) the insulin-signaling pathway involved in regulating the expression of LCFA transporters. Our results demonstrate that insulin rapidly upregulated FAT/CD36, but not FABPpm, protein expression, via the phosphatidylinositol (PI) 3-kinase-signaling pathway. This increase in FAT/CD36 expression was accompanied by an increased plasmalemmal content of FAT/CD36, which increased the rate of LCFA transport into giant vesicles.
METHODS

Materials.
The PI 3-kinase inhibitor LY-294002 and MEK1/2 kinase inhibitor UO-126 were purchased from Cell Signaling Technology (Beverly, MA), and a PKC inhibitor (myristoylated PKC pseudosubstrate) was purchased from Calbiochem (San Diego, CA). Primary antibodies used in this study were as follows. FAT/CD36 and FABPpm were detected using the MO25 antibody (22) and FABPpm antisera (7) Animals and isolation of cardiac myocytes. Male Wistar Rats (250 -300 g) were bred on site and maintained at 20°C on a reverse light-dark cycle in approved animal holding facilities. They had unrestricted access to food and water. This study was approved by the committee on animal care at the University of Guelph.
Cardiac myocytes were isolated from male adult rats according to the procedure described by Fisher et al. (11) , as modified by Luiken et al. (19) . Briefly, rats were anesthetized using Somnotol (50 -60 mg/100 g ip) combined with heparin (300 IU/100 g ip). The hearts were quickly removed and placed in ice-cold Krebs-Henseleit bicarbonate buffer (KHB, pH 7.4) and equilibrated with 95% O 2-5% CO2. Subsequently, hearts were perfused (20 min) in a recirculating mode with KHB buffer supplemented with 0.7% (wt/vol) BSA, 15 mM butanedione monoxime, and 0.075% (wt/vol) collagenase type II. CaCl 2 was added to a final concentration 0.2 mM during the perfusion. After 20 min, hearts were removed and gently minced. The suspension was incubated for another 10 min at 37°C while the CaCl 2 concentration was gradually raised to 1.0 mM. Cells were then filtered through a 0.2-mm nylon gauze and centrifuged for 2 min at 20 g. After isolation, cells were washed twice and suspended in 20 ml of medium A [KHB buffer supplemented with 2% (wt/vol) BSA and 1 mM CaCl 2]. At the beginning of the experiments, the percentage of rod-shaped cells excluding trypan blue was determined. For all the experiments Ͼ80% of the cardiac myocytes were structurally intact. For determination of cardiac myocyte wet mass, duplicate aliquots of the cells suspensions were centrifuged (2-3 s at 10,000 g). The yield of cardiac myocytes ranged from 500 to 600 mg per single heart.
Effects of insulin on FAT/CD36 and FABPpm and cardiac myocyte viability. The effects of insulin on cardiac myocyte FAT/CD36 and FABPpm were examined during time course studies (10 nM insulin, 0 -180 min; typically experiments were conducted over 120 min) and dose-response studies (0 -100 nM insulin, 2 h). All studies were performed at 37°C. Viability was assessed in freshly obtained cardiac myocytes immediately after their isolation and after 2-4 h of incubation. Cardiac myocyte ATP content was determined after acidification of cell samples with ice-cold perchloric acid (final concentration 0.5 M), as described by Williamson and Corkey (33) . The metabolically competent and dead myocytes were distinguished using a commercially available kit for cell viability (Cytotoxity/Viability Kit L-3224; Molecular Probes, Eugene, OR).
Determining insulin-signaling pathways involved in regulating LCFA transporter expression. To ascertain the signaling pathways involved in the insulin-induced regulation of LCFA transporters, cardiac myocytes were pretreated for 1 h with selected inhibitors followed by treatment with insulin (10 nM for 2 h). The inhibitors used were as follows: myristoylated PKC/ pseudosubstrate inhibitor (PKC-ps, 10 M) has been used as a cell-permeable specific inhibitor of PKC/ kinases (24); UO-126 has been used at a concentration of 10 M as a highly selective inhibitor of the MAP kinases MEK1 and MEK2 (10); LY-294002 was shown to act as highly selective inhibitor of PI 3-kinase and at a concentration of 50 M does not inhibit lipid and protein kinases such as PI 4-kinase, PKC, or MAP kinase (31) .
Effects of insulin on LCFA uptake by cardiac myocytes. To examine the effects of 2-h insulin (10 nM) exposure on palmitate uptake by cardiac myocytes, we used the procedure of Luiken et al. (19) . For these purposes, 0.6 ml of a [1- 14 C]palmitate-BSA complex was added to 1.8 ml of cardiomyocyte suspension (final palmitate concentration 100 M, palmitate/BSA ratio of 0.3). Palmitate uptake was stopped by adding an ice-cold stop solution [KHB supplemented with 0.1% BSA (wt/vol), 1 mM CaCl2, and 0.2 mM phloretin]. Subsequently, cells were washed twice with the stop solution at 60 g for 2 min. The final pellet was assayed for radioactivity.
Subcellular fractionation of cardiac myocytes. To detect the subcellular distribution of FAT/CD36 and FABPpm, plasma membranes (PM) and low-density microsomes (LDM), were isolated from cardiac myocytes. Isolated cardiac myocytes (50 mg wet mass/ml) were incubated with medium A and constantly gassed with 95% O2-5% CO2 with (10 nM) or without insulin for 2 h. At the end of the experiments, NaN3 was added (final concentration 5 mM), and samples were frozen in liquid N2 and kept at Ϫ80°C until analyzed. Subsequently, PM and LDM fractions were obtained as we (19) have previously described. Briefly, on being thawed, cardiac myocytes were centrifuged for 15 min at 17,000 g. The pellet was then washed with TES buffer (20 mM Tris, pH 7.4, 1 mM EDTA, 250 mM sucrose, and 100 M PMSF) and centrifuged for 20 min at 17,000 g. Thereafter, the resuspended pellet was homogenized (10 strokes) in a glass homogenizer, and the total volume was layered on top of a sucrose cushion (38% wt/vol) in 15 ml of Tris, pH 7.4, containing 1 mM EDTA. Subsequently, samples were centrifuged for 65 min at 65,000 g. The interface was collected, diluted with 20 ml of TES buffer, and pelleted at 48,000 g for 30 min. The final pellet yielded the PM, and this was resuspended in 100 l of TES buffer. For the collection of intracellular membrane pools, the supernatant fraction from the first 17,000-g centrifugation step was collected and centrifuged for 30 min at 48,000 g. The resulting in supernatant fraction was centrifuged for 65 min at 250,000 g. This yielded LDM, which were resuspended in 100 l of TES buffer. In the LDM fraction there was no mitochondrial contamination, as determined by the absence of the mitochondrial enzyme cytochrome oxidase (data not shown). We have previously reported that the PM fraction was enriched with the ouabain-sensitive p-nitrophenylphosphatase (13.5-fold enrichment) accompanied by the decrease in sarcoplasmatic EGTA-sensitive Ca 2ϩ -ATPase (3.6-fold decline) (19) .
Heart perfusion, giant vesicle preparation, and LCFA transport. Isolated hearts were perfused with (10 nM) or without insulin in a Langendorff mode, using continuously gassed (95% O2-5% CO2) medium A. After 2 h, the ventricles were removed and frozen in liquid N2 and stored at Ϫ80°C until analyzed for FAT/CD36 and FABPpm by use of Western blot analysis.
Before preparation of giant sarcolemmal vesicles, hearts were perfused with (10 nM) and without insulin for 2 h. Thereafter, the ventricles were removed and placed in KCl-MOPS buffer (140 mM KCl, 10 mM MOPS, pH 7.4). Giant sarcolemmal vesicles were prepared as we have previously reported (18, 20) . Briefly, perfused ventricles were scored into strips with a scalpel and incubated for 1 h at 34°C in KCl-MOPS supplemented with 0.142 mg/ml PMSF, 10 mg/ml aprotinin, and 150 U/ml type II collagenase. The incubation medium was collected, and the ventricles were washed with 10 mM EDTA in KCl-MOPS until 7 ml had been collected. Percoll was added to the collected medium in a volume ratio of 7:30. This mixture was slowly pipetted under a density gradient of 3 ml of 4% (wt/vol) Nycodenz, on top of which 1 ml of KCl-MOPS was layered. The samples were centrifuged in a swinging bucket rotor (Beckman) at 60 g for 45 min at room temperature. After centrifugation, the vesicles were collected from the interface between the Nycodenz and KCl-MOPS solutions. The vesicles were pelleted at 12,000 g for 5 min at room temperature. The supernatant was aspirated, and the vesicles were slightly diluted with KCl-MOPS supplemented with PMSF. Vesicles were used immediately for LCFA transport. Some vesicles were also stored at Ϫ80°C until analyzed for plasmalemmal LCFA transporters.
LCFA transport was performed as we have previously reported (18, 20 1%BSA-KCl-MOPS) was added and the sample immediately centrifuged (12,000 g, 2 min). The supernatant fraction was aspirated, and the bottom of the tube containing the pellet was cut off and placed in a scintillation vial. Standard liquid scintillation techniques were used to measure the radioactivity.
Western blot analysis. FAT/CD36 and FABPpm were determined in heart homogenates and in cardiac myocytes, as well as in the PM and LDM fractions derived from cardiac myocytes. In addition, these proteins were also determined in giant vesicle PM prepared from whole hearts. We used routine Western blotting procedures as previously described (5, 16 -19) to detect FAT/CD36 and FABPpm, as well as some other proteins to which we refer but for which the data have not been shown. Briefly, all samples were separated using 10% SDS-polyacrylamide gel electrophoresis, and polyclonal antiserum was applied. Membranes were immunoblotted with MO25 antibody against FAT/CD36, FABPpm antisera, anti-phospho-Akt1/2/3 (Ser Northern blot analysis. Total RNA was isolated from cardiac myocytes using TriPure Isolation Reagent (Roche, Indianapolis, IN). Total RNA (3-5 g) was loaded on a formaldehyde gel for each sample, electrophoresed at 100 V for 2.5 h, and transferred to positively charged nylon membranes (Roche). Equal loading of RNA and even transfers were confirmed by Blot Stain Blue (Sigma-Aldrich, Oakville, ON, Canada). FAT/CD36 and FABPpm digoxigenin (DIG)-labeled probes were generated using a DIG RNA labeling mix (Roche). Membranes were prehybridized for 30 -60 min at 68°C in a standard hybridization buffer [containing 25% (FAT/CD36) or 50% (FABPpm) deionized formamide, 5ϫ SSC, 0.1% N-lauroylsarcosine, 0.02% SDS, and 2ϫ Blocking Solution (Roche)]. Membranes were hybridized overnight at 68°C in 1 g of DIG-labeled probe per 10 ml of hybridization buffer. Membranes were washed, blocked in 1ϫ Blocking Solution for 30 min, and incubated with anti-DIG-AP antibody (1:10 000) for 30 min. Signal detection was performed using CDP-Star chemiluminescent substrate (Roche). Blots were visualized and quantified using the ChemiGenius 2 Bio Imaging System (Perkin Elmer, Boston, MA).
Statistics. All presented data are expressed as means Ϯ SE. Depending on the experiment, statistical differences were tested with analyses of variance and Fisher's least significant differences post hoc test or with a t-test. Statistical significance was set at P Ͻ 0.05.
RESULTS
Cardiac myocyte viability.
Before the experiments, we assessed the viability of cardiac myocytes, incubated up to 4 h, by using viability tests of the myocytes and determining their ATP concentrations. During 2-4 h of incubation, cardiac myocytes remained morphologically unchanged. Cell death was small (3% during 2-h incubations), and ATP concentrations were only minimally reduced (Ͻ7%). Hence, the incubated cardiac myocytes cells were structurally intact and metabolically viable. Furthermore, the inhibitors used in this study did not affect cell survival (data not shown).
Effects of insulin on cardiac myocyte FABPpm and FAT/ CD36. We exposed freshly isolated cardiac myocytes to 10 nM insulin for varying periods of time. In the presence of insulin (10 nM), FAT/CD36 protein was increased over the 2-h period (Fig. 1A) . No changes were observed within the first 30 min, but after 1 h, FAT/CD36 protein had increased by 25% (P Ͻ 0.05), reaching a plateau after 90 min (ϩ51%, P Ͻ 0.05; Fig.  1A ). When myocytes were not exposed to insulin, FAT/CD36 concentrations were not different from freshly obtained controls (P Ͼ 0.05; Fig. 1A) .
Compared with freshly obtained cardiac myocytes (t ϭ 0), insulin had no effect on FABPpm protein expression. Over a 2-h period, FABPpm was only minimally reduced by insulin (Ͻ7%). This did not differ from FABPPpm in cardiac myocytes incubated without insulin for 2 h (P Ͼ 0.05; Fig. 1B) .
We also examined the dose-response effects of insulin (10 Ϫ12 to 10 Ϫ7 M). Increasing concentrations of insulin did not alter FABPpm (P Ͼ 0.05; Fig. 2 ). In contrast, there was a dose-dependent relationship between insulin and FAT/CD36 expression (P Ͻ 0.05; Fig. 2 ). Compared with fresh (t ϭ 0), untreated cardiac myocytes, a 2-h exposure to 10 Ϫ10 M insulin resulted in a 9% increase in FAT/CD36 (P Ͻ 0.05). Thereafter, FAT/CD36 protein increased progressively to ϩ20% at 5 ϫ 10 Ϫ10 M insulin and reached a plateau at 10 Ϫ9 to 10 Ϫ8 M (45-48%) insulin (P Ͻ 0.05; Fig. 2 ).
The 2-h insulin exposure increased FAT mRNA by ϩ245% (P Ͻ 0.05; Fig. 3 ). Concomittantly, FABPpm mRNA abundance was not altered (Fig. 3) .
Effects of insulin on FABPpm and FAT/CD36 in the heart. To examine whether insulin-stimulated upregulation of FAT/ CD36 also occurs in the intact heart, we investigated the effect of insulin on the expression of LCFA transporters in Langendorff-perfused hearts. Perfusion of the hearts for 2 h with 10 nM insulin increased FAT/CD36 expression by 32% (P Ͻ 0.05; Fig. 4) . The response to insulin in these two preparations was remarkably similar (Fig. 4) ; over a 2-h period the insulininduced increase in heart FAT/CD36 (ϩ32%) did not differ from the insulin-induced increase in cardiac myocytes (ϩ43%, P Ͼ 0.05). The effects of insulin were observed for only one of the LCFA transporters, as only FAT/CD36 was increased but not FABPpm, in both cardiac myocytes and in the intact, Langendorff-perfused heart (Fig. 4) .
Effects of insulin on subcellular distribution of FAT/CD36 and FABPpm.
To examine the effects of insulin on the subcellular distribution of FAT/CD36, we determined the FAT/ CD36 in PM and LDM obtained from cardiac myocytes. When cardiac myocytes were exposed briefly to insulin (30 min) before any changes in FAT/CD36 expression occurred (Fig. 1A ), we observed that insulin induced the translocation of FAT/CD36 from LDM to the PM (data not shown). These results confirmed the observations that we recently made (19) . When FAT/CD36 expression was increased by insulin after 2 h (Figs. 1A and 5A) , there was also a further increase in FAT/ CD36 at the PM (ϩ53%, P Ͻ 0.05; Fig. 5A ), whereas FAT/ CD36 was concomitantly reduced by 20% in the LDM (P Ͻ 0.05; Fig. 5A ). Interestingly, a new observation was the presence of FABPpm in both the PM and the LDM. However, insulin failed to alter the expression of FABPpm (Figs. 1B and 5B), and insulin also failed to redistribute FABPpm, from the LDM to the PM, after either 30 min (data not shown) or 2 h (Fig. 5B) .
Effects of insulin on LCFA transporters and LCFA transport into giant vesicles. To determine whether the insulin-induced increase in FAT/CD36 altered LCFA flux into heart, we examined rates of LCFA transport into giant sarcolemmal vesicles prepared from insulin-perfused hearts. Although no changes in FABPpm expression or its sarcolemmal content were observed (Fig. 6, A and B) , insulin increased the expression of FAT/CD36 (ϩ32%, P Ͻ 0.05; Fig. 6A ). In the giant vesicles, the PM FAT/CD36 content was also increased (ϩ29%, P Ͻ 0.05; Fig. 6B ), and the rate of palmitate transport into giant vesicles was increased to the same extent (ϩ34%, P Ͻ 0.05; Fig. 6C ).
Signaling pathways that provoke insulin-induced FAT/CD36 expression. We examined through which of the postreceptor signaling pathways insulin provoked an increase in total FAT/ CD36 content. As has been shown previously (26, 29) , exposure (5 min) of cardiac myocytes to insulin increased the phosphorylation of Akt (Ser 473 and Thr 308 ), ERK1/2, and PKC/, and these insulin-induced phosphorylations were blocked by LY-29004, UO-126, and PKC-ps, respectively (data not shown). Blocking of the PKC/-signaling pathway did not inhibit the insulin-induced expression of FAT/CD36 (P Ͼ 0.05; Fig. 7) , whereas UO-126 only partially inhibited the insulin-induced FAT/CD36 expression (Fig. 7) . In contrast, when the PI 3-kinase-signaling pathway was blocked by LY-29004, the insulin-induced increase in FAT/CD36 expression was completely inhibited (Fig. 7) . When the increase in FAT/ CD36 expression was blocked by LY-29004, insulin also failed to stimulate LCFA uptake into cardiac myocytes, whereas blocking of the other insulin-signaling pathways failed to inhibit the insulin-stimulated LCFA uptake (Fig. 8 ).
DISCUSSION
In a previous study (19) , we showed that insulin induced the translocation of FAT/CD36 from an intracellular depot to the plasma membrane in cardiac myocytes and the heart. In the present study, we have now identified another, previously unknown role for insulin. Specifically, 1) insulin very rapidly upregulated the expression of the LCFA transport protein FAT/CD36 in a time-and dose-dependent manner; 2) insulin's effects on FAT/CD36 protein expression were quantitatively similar in cardiac myocytes and the intact heart; and 3) the insulin-induced stimulation of FAT/CD36 expression occurred via the PI 3-kinase-signaling pathway. In contrast, 4) insulin failed to alter the expression of another LCFA transporter, FABPpm. There were also important functional consequences of the insulin-induced upregulation of FAT/CD36, as 5) the insulin-induced increase in FAT/CD36 also targeted a substantial portion of the FAT/CD36 to the plasma membrane, and 6) this resulted in a quantitatively similar increase in the rate of palmitate transport into giant vesicles. Thus our studies indicate that insulin, besides its well-known role in glucose transport and metabolism, also has a key role in regulating the Fig. 3 . Effects of insulin on FAT/CD36 (A) and FABPpm mRNA (B) in cardiac myocytes. Cardiac myocytes were prepared from rat hearts and incubated for 2 h at 37°C in the absence and presence of insulin (10 nM) as described in METHODS. Untreated controls at 0 min were not incubated or exposed to insulin. Data are based on 3-4 independent determinations at each time point (means Ϯ SE). *P Ͻ 0.05 insulin-treated cardiac myocytes at 120 min vs. untreated cardiac myocytes at 0 and at 120 min.
Fig. 4. Effects of insulin on FAT/CD36 (A)
and FABPpm (B) protein expression in cardiac myocytes and Langendorff-perfused hearts. Cardiac myocytes were prepared from rat hearts and incubated for 2 h at 37°C in the absence and presence of insulin (10 nM), as described in METHODS. Hearts were perfused for 2 h at 37°C in Langendorff mode in the absence and presence of insulin (10 nM) as described in METHODS. Data are based on 4 independent determinations for cardiac myocytes and perfused hearts (means Ϯ SE). *P Ͻ 0.05, 0 vs. 120 min in cardiac myocytes and the heart. At 120 min, FAT/CD36 and FABPpm protein expression did not differ between cardiac myocytes and the heart (P Ͼ 0.05). and FABPpm proteins in plasma membranes (PM) and low-density microsomes (LDM) prepared from cardiac myocytes. Cardiac myocytes were prepared from rat hearts and incubated for 2 h at 37°C in the absence and presence of insulin (10 nM) as described in METHODS. Subcellular fractions were prepared from these cardiac myocytes as described in METHODS. Basal conditions in each experiment are set to 100%. The very small error bar in LDM (A) does not show up because of the scale of the ordinate. Data are based on on 5 independent determinations (means Ϯ SE). *P Ͻ 0.05, insulin vs. basal. Fig. 6 . Effects of insulin perfusion of intact hearts on FAT/CD36 and FABPpm expression in heart homogenates (A), on giant vesicle PM FAT/CD36 and FABPpm protein content (B), and on rates of palmitate transport into giant vesicles (C). Hearts were perfused in Langendorff mode at 37°C for 2 h in the absence and presence of insulin (10 nM) as described in METHODS. Thereafter, giant vesicles were prepared as described in MATERIALS AND METHODS, and rates of palmitate transport into giant vesicles were determined as described in METHODS. Western blot analysis was performed on heart homogenates and PM derived from giant vesicles as described in METHODS. Data are based on 3-4 independent determinations for each treatment (means Ϯ SE). *P Ͻ 0.05, insulin vs. basal. transport of LCFAs 1) by targeting FAT/CD36 to the plasma membrane and 2) by regulating the expression of the LCFA transporter FAT/CD36.
Interestingly, the present studies have also shown that insulin does not regulate the expression of FABPpm, another LCFA transporter. Unexpectedly, we found that FABPpm is present not only at the plasma membrane, as is well known, but also in an intracellular low-density microsome depot. It is known that FABPpm is identical to the mitochondrial aspartate aminotransferase (6, 14, 28) . However, the low-density microsome fraction is devoid of mitochondrial contamination (data not shown). The intracellular FABPpm pool, unlike the intracellular FAT/CD36 pool, is not a target for insulin-induced translocation. Possibly, other stimuli induce the translocation of FABPpm.
Except for the report by Man et al. (21), we are not aware of any studies that have examined the effects of insulin on the expression of LCFA transporters. It is worth noting that Man et al. found that insulin repressed the expression of FATP1 mRNA by 66% after 24 h (t 1/2 ϭ 4 h) in 3T3-L1 adipocytes, although neither the effects on protein expression nor the effects on LCFA transport were examined. It is important to do so, because there seems to be little relationship between LCFA transporter mRNAs and their protein products and between LCFA transporter mRNAs and rates of LCFA transport (1, 2, 16, 17) . In contrast to the studies showing that insulin repressed FATP1 mRNA expression in 3T3-L1 adipocytes (21), we observed in cardiac myocytes that insulin markedly stimulated the protein expression of the LCFA transporter FAT/CD36, but not the LCFA transporter FABPpm. The insulin induction of FAT/CD36 expression was very rapid, with an increased protein expression being observed after only 1 h and continuing to increase further for another 30 min. Thereafter, FAT/CD36 remained stably overexpressed from minutes 90 to 120. We also observed a strikingly similar effect of the insulin-induced expression of FAT/CD36 in cardiac myocytes and in the intact heart, suggesting that our observations are relevant in vivo. In other studies, a rapid increase in protein expression and mRNA by a variety of stimuli has been observed in muscle tissue [i.e., 1.5-to 6-fold increase in uncoupling protein-3 in 30 -200 min (34) ]. Thus the rapidly induced increase in FAT/CD36 protein expression by insulin within 2 h is well within the timeline of those studies. The increased FAT/CD36 protein expression would appear to be mediated by pretranslational events, as insulin rapidly increases FAT/CD36 mRNA within this time period. An insulin-induced upregulation of FAT/CD36 mRNA has also been reported by others (23) . In marked contrast, insulin did not affect the expression of FABPpm protein or its transcript. Thus, in our present study and others (21), insulin has unique effects on the expression of LCFA transporters; this hormone represses FATP1 mRNA (21) in 3T3-L1 adipocytes, does not regulate the expression of FABPpm in cardiac myocytes and the intact heart (present study), and upregulates the expression of FAT/CD36 in cardiac myocytes and the intact heart (present study). Although this may indicate that there are tissue-specific responses to insulin (i.e., 3T3-L1 adipocytes vs. cardiac myocytes), there can be no doubt that in the same tissue (heart) insulin differentially regulates the expression of two LCFA transporters, FAT/CD36 and FABPpm.
Recent studies have provided evidence that different signaling pathways can contribute to protein synthesis in cardiac myocytes (15, 32) , and insulin can activate a number of signaling pathways (26, 29) . Blocking insulin signaling through the MAP kinase-and PKC/-signaling pathways failed to inhibit the insulin-induced increase in FAT/CD36 Fig. 7 . Effects of insulin and insulin ϩ inhibitors on expression of FAT/CD36 proteins in cardiac myocytes. The following inhibitors were used: myristoylated PKC/ pseudosubstrate inhibitor (PKC-ps, 10 M), inhibitor of MAP kinases UO-126 (UO, 10 M), inhibitor of phosphatidylinositol 3-kinase LY-294002 (LY, 50 M). Cardiac myocytes were preincubated for 1 h at 37°C in the absence and presence of the inhibitors, followed by incubation with insulin (10 nM) for 2 h as described in METHODS. Data are based on 3 independent determinations for each treatment (means Ϯ SE). *P Ͻ 0.05, treatment vs. control; **P Ͻ 0.05, UO vs. insulin (no inhibitor). Fig. 8 . Effects of insulin and insulin ϩ inhibitors on rate of palmitate uptake by cardiac myocytes. Inhibitors used were as in Fig. 7 . Cardiac myocytes prepared from rat hearts were preincubated for 1 h at 37°C in the absence and presence of inhibitors, followed by incubation with insulin (10 nM) for 2 h, and immediately thereafter the rate of palmitate uptake was determined as described in METHODS. Data are based on 3 independent determinations for each treatment (means Ϯ SE). *P Ͻ 0.05, treatment vs. control.
expression. In contrast, we observed a complete inhibition of the insulin-induced expression of FAT/CD36 when the PI 3-kinase pathway was blocked. Thus the insulin-PI 3-kinaseAkt-signaling pathway must be activated to stimulate the expression of FAT/CD36. Recently, it was shown that the insulin-induced activation of Akt1 is required for growth (9) , and possibly other functions, whereas the insulin-induced activation of Akt2 is essential to maintain normal glucose homeostasis (8) . Whether insulin activation of Akt1 or Akt2 is required to induce the upregulation of FAT/CD36 remains to be established.
An important feature of the present studies is that we also examined the metabolic consequences of insulin-induced overexpression of FAT/CD36. For these purposes we 1) subfractionated cardiac myocytes to examine the effects of insulin on the subcellular distribution of FAT/CD36, 2) determined the plasmalemmal content of FAT/CD36 in giant vesicles, into which 3) we had examined the rates of palmitate transport. In agreement with our previous work (18, 19) , insulin induced the translocation of FAT/CD36 from an intracellular depot to the plasma membrane within 30 min, before any changes in FAT/CD36 expression had occurred (data not shown). With more prolonged exposure to insulin (2 h) there were two effects: 1) FAT/CD36 expression was increased, and 2) the plasmalemmal FAT/CD36 was also further increased whereas the intracellular depot was decreased. Specifically, if the acute (30 min) insulin stimulation studies provide an index of the insulin-induced FATCD36 translocation to the plasma membrane, when FAT/CD36 expression is not altered (data not shown and Ref. 19) , then the greater increase in plasmalemmal FAT/CD36 observed after 2 h of insulin exposure would seem to reflect the sum of the combined effects of 1) the insulininduced expression of FAT/CD36 protein and 2) the insulininduced translocation of FAT/CD36 to the plasma membrane. Thus insulin not only increases FAT/CD36 expression, but it also targets a similar proportion of this increase to the plasma membrane.
Our study also provides strong evidence that FAT/CD36, is involved with plasmalemmal LCFA transport. An increase in LCFA transport occurred only when plasmalemmal FAT/ CD36 was increased, whereas no change in LCFA transport occurred when the insulin-induced effects on FAT/CD36 expression and translocation were blocked by LY-29004. We have previously shown that blocking FAT/CD36 specifically with a reactive ester (sulfo-N-succinimidyl oleate) inhibited LCFA transport (4, 20) . Interestingly, insulin induced similar increases in palmitate transport (ϩ34%) and plasmalemmal FAT/CD36 (ϩ29%), as well as a similar increase in triacylglycerol esterification (ϩ36%; data not shown). These observations underscore the fact that insulin can have a profound effect on LCFA uptake into the heart. This may be most relevant in the postprandial period, when insulin clears not only glucose from the circulation but apparently also LCFAs.
Previously, we (16) had observed in a model of STZinduced diabetes that FAT/CD36 expression in the heart was increased. Thus it was tempting to ascribe these observations to the hypoinsulinemia in that model. However, the present results indicate that, under controlled conditions, insulin acts to increase the expression of FAT/CD36 in the heart. It would seem, therefore, that, in the STZ-induced diabetes model, the hypoinsulinemia may not have been at the root of the increased FAT/CD36 expression. In this model of diabetes, perturbations in circulating substrates also occur, and it is conceivable that the increased concentration of glucose and/or fatty acids, along with the concurrent hypoinsulinemia, contributed to the increased expression of FAT/CD36. This suggestion awaits confirmation by carefully controlled experiments in isolated hearts and cardiac myocytes.
In summary, we have shown that insulin induces the expression of the LCFA transporter FAT/CD36 in cardiac myocytes and the intact heart. The insulin-induced increase in FAT/ CD36 expression is mediated via the PI 3-kinase-signaling pathway. The functional consequence of the insulin-induced increase in FAT/CD36 expression is an increased rate of LCFA transport across the plasma membrane, which was quantitatively similar to the increase in FAT/CD36 expression and the increase in plasmalemmal FAT/CD36 content. Thus insulin not only increased FAT/CD36 protein expression, but this hormone also targeted FAT/CD36 to the plasma membrane. Our studies also revealed that insulin failed to increase the expression of FABPpm. Unexpectedly, we found that FABPpm is present not only at the plasma membrane, but also in an intracellular depot. But, although insulin induced the translocation of FAT/CD36 from the intracellular depot to the plasma membrane, insulin failed to translocate FABPpm.
